Compare ETSY & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETSY | GPCR |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.5B |
| IPO Year | 2015 | 2023 |
| Metric | ETSY | GPCR |
|---|---|---|
| Price | $58.23 | $89.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 27 | 12 |
| Target Price | $62.55 | ★ $103.09 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $2,854,027,000.00 | N/A |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $2.96 | N/A |
| P/E Ratio | $32.56 | ★ N/A |
| Revenue Growth | ★ 1.98 | N/A |
| 52 Week Low | $40.05 | $13.22 |
| 52 Week High | $76.52 | $94.90 |
| Indicator | ETSY | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 71.50 |
| Support Level | $59.60 | $87.00 |
| Resistance Level | $64.51 | $94.77 |
| Average True Range (ATR) | 2.24 | 5.19 |
| MACD | -0.32 | 0.45 |
| Stochastic Oscillator | 8.86 | 81.77 |
Etsy operates a top-10 e-commerce marketplace in the US and the UK, with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $12.5 billion in 2024 consolidated gross merchandise volume, Etsy has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. The firm connects about 95 million buyers and 8 million sellers on its marketplace properties: Etsy and Depop (clothing resale).
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.